Agilent Joins AMBIC to Advance Biomanufacturing

ColumnMay 2022
Volume 18
Issue 05
Pages: 12

Agilent Technologies Inc. (California, USA) has announced that it has become a member of the Advanced Mammalian Biomanufacturing Innovation Center (AMBIC), to demonstrate the company’s commitment to partnering to support the provision of the next generation of analytical tools and comprehensive solutions needed by academic, pharmaceutical, and clinical researchers. “Our customers recognize the need to improve biotherapeutic manufacturing,” said Darlene Solomon, Senior VP and CTO at Agilent. “Working with AMBIC we look forward to advancing technologies.” There is a growing need to rapidly assess critical process and product quality attributes to support biotherapeutics manufacturing and facilitate adaptive process controls. AMBIC brings together leading academic and industrial biotechnologists, who are focused on mammalian cell culture manufacturing.

Its mission is to develop enabling technologies, knowledge, design tools, and methods that apply and integrate high-throughput and genome-based technologies to fast-track advanced biomanufacturing processes. Through systems-level biology analysis, novel cell‑line development, bioreactor optimization, and advanced analytics, AMBIC aims to provide transformative solutions that can lower biomanufacturing costs and improve bioprocessing efficiency. For more information, please visit:

Related Videos
Toby Astill | Image Credit: © Thermo Fisher Scientific
Related Content